Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Tarsus Pharmaceuticals, Inc. (TARS) had Receiveable Turnover of 5.18 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$451.36M |
|
$-66.42M |
|
$30.68M |
|
$420.68M |
|
$522.33M |
|
$-70.97M |
|
$6.61M |
|
$-64.36M |
|
$-64.36M |
|
$-66.42M |
|
$-66.42M |
|
$-66.42M |
|
$-66.42M |
|
$-70.97M |
|
$-74.04M |
|
41.78M |
|
41.78M |
|
$-1.59 |
|
$-1.59 |
|
| Balance Sheet Financials | |
$522.78M |
|
$11.66M |
|
$39.38M |
|
$562.16M |
|
$135.69M |
|
$72.44M |
|
$83.04M |
|
$218.73M |
|
$343.43M |
|
$336.06M |
|
$343.43M |
|
42.55M |
|
| Cash Flow Statement Financials | |
$-12.45M |
|
$-42.12M |
|
$143.39M |
|
$97.38M |
|
$186.20M |
|
$88.82M |
|
$41.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.85 |
|
-- |
|
-- |
|
0.17 |
|
0.21 |
|
93.20% |
|
-15.72% |
|
-15.72% |
|
-16.40% |
|
-14.26% |
|
-14.72% |
|
$-22.31M |
|
-- |
|
-- |
|
-- |
|
0.80 |
|
7.02 |
|
|
Receiveable Turnover |
5.18 |
70.44 |
|
-19.34% |
|
-19.76% |
|
-11.81% |
|
-15.97% |
|
$8.07 |
|
$-0.53 |
|
$-0.30 |
|